Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
The Medical Journal of Australia
|
March 31, 2022
In-transit cutaneous squamous cell carcinoma
Luke S McLean, Danny Rischin
Immunotherapy
|
January 29, 2026
Cemiplimab in the treatment of cutaneous squamous cell carcinoma
Luke S McLean, Annette M Lim, Danny Rischin
International Journal of Clinical Oncology
|
June 11, 2026
BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy
Yael R Lefkovits, Luke S McLean, Mark R Middleton, et al.
Drugs & Aging
|
March 6, 2024
Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma
Luke S McLean, Annette M Lim, Mathias Bressel, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
March 19, 2024
Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy
Karda Cavanagh, Luke S McLean, Annette M Lim, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
October 14, 2021
FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma
Luke S McLean, Karda Cavanagh, Rodney J Hicks, et al.
Frontiers in Oncology
|
February 4, 2022
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma
Luke S McLean, Annette M Lim, Angela Webb, et al.
Investigational New Drugs
|
April 18, 2022
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin
Luke S McLean, Tessa A Morris, Ann Gramza, et al.
Journal of the American Academy of Dermatology
|
November 30, 2025
Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study
Catherine Bennett, Luke S McLean, Annette M Lim, et al.
Cancers
|
April 27, 2024
A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors
Luke S McLean, Annette M Lim, Christopher Angel, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
The Medical Journal of Australia
|
March 31, 2022
In-transit cutaneous squamous cell carcinoma
Luke S McLean, Danny Rischin
Immunotherapy
|
January 29, 2026
Cemiplimab in the treatment of cutaneous squamous cell carcinoma
Luke S McLean, Annette M Lim, Danny Rischin
International Journal of Clinical Oncology
|
June 11, 2026
BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy
Yael R Lefkovits, Luke S McLean, Mark R Middleton, et al.
Drugs & Aging
|
March 6, 2024
Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma
Luke S McLean, Annette M Lim, Mathias Bressel, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
March 19, 2024
Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy
Karda Cavanagh, Luke S McLean, Annette M Lim, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
October 14, 2021
FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma
Luke S McLean, Karda Cavanagh, Rodney J Hicks, et al.
Frontiers in Oncology
|
February 4, 2022
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma
Luke S McLean, Annette M Lim, Angela Webb, et al.
Investigational New Drugs
|
April 18, 2022
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin
Luke S McLean, Tessa A Morris, Ann Gramza, et al.
Journal of the American Academy of Dermatology
|
November 30, 2025
Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study
Catherine Bennett, Luke S McLean, Annette M Lim, et al.
Cancers
|
April 27, 2024
A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors
Luke S McLean, Annette M Lim, Christopher Angel, et al.
Page
of 2